Open AccessThe Presence of CA19‐9 in Serum and Saliva from Lewis Blood‐group Negative Cancer Patients
Author(s) -
Yazawa Shin,
Asao Takayuki,
Izawa Hideaki,
Miyamoto Yukio,
Matta Khushi L.
Publication year - 1988
Publication title -
japanese journal of cancer research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.035
H-Index - 141
eISSN - 1349-7006
pISSN - 0910-5050
DOI - 10.1111/j.1349-7006.1988.tb01624.x
Subject(s) - saliva , fucosyltransferase , abo blood group system , cancer , fucose , antigen , group a , immunology , medicine , gastroenterology , endocrinology , microbiology and biotechnology , biology , biochemistry , glycoprotein , enzyme
Eighteen cancer patients showed high levels of CA19‐9 in sera, even though the blood‐group phenotypes of their red blood cells were Le(a — b —). Seven of these patients (group I) were determined as Le(a — b —) from both red blood cells and saliva consistently, whereas eleven other patients (group II) secreted either Le a or Le b antigen in saliva and showed the expression of incompatible Lewis blood‐group antigens. GDP‐fucose: N ‐acetyl‐glucosaminide a (1 × 4)‐L‐fucosyltransferase was demonstrated to be present in salivas from both group I and group II. These results suggest that a cancer‐associated alteration of Lewis blood‐group antigen expression occurs in cancer patients.